Lv6
2290 积分 2023-03-12 加入
Utilizing Molecular Dynamics and Mechanistic Pharmacokinetic Studies in the Design of Selective CDK2 Inhibitors
14天前
已完结
PRMT5: A Promising Synthetical Lethal Target for MTAP-Deleted Cancers
27天前
已完结
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers
28天前
已完结
146 (PB134): First disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies
28天前
已完结
Targeting Multiple KRAS Mutations with High-Affinity Macrocyclic Inhibitors: From Discovery to Preclinical Validation
1个月前
已完结
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation
1个月前
已完结
Discovery of INCB123667, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of cyclin E dysregulated cancers
1个月前
已完结
Antibody-Mediated Delivery of BRM/BRG1 Protein Degraders Affords Strong Antitumor Efficacy in Multiple BRM-Dependent Non-Small Cell Lung Cancer Xenograft Models
1个月前
已完结
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy
1个月前
已完结
Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies
1个月前
已完结
皖公网安备34019202002308
